Sugi Predict

Sugi Predict / Compounds / SCHEMBL5217666

SCHEMBL5217666

SCHEMBL5217666

CN1CCN(CCOc2ccc(C=O)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 2/20 0.62
▸ ALDH1A1 P00352 4/20 0.54
▸ HPGD P15428 2/20 0.54
▸ USP2 O75604 1/20 0.54
▸ KDM4E B2RXH2 1/20 0.52
▸ RAB9A P51151 2/20 0.51
▸ NPC1 O15118 1/20 0.51
▸ PSMB1 P20618 1/20 0.50
▸ PSMB5 P28074 1/20 0.50
▸ PSMB2 P49721 1/20 0.50
▸ DRD3 P35462 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ SIGMAR1 Q99720 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4731940 0.92 RAB9A (0.61) LTA4HALDH1A1HPGDUSP2RAB9A
SCHEMBL2249200 0.87 LTA4H (0.68) LTA4HHPGDKDM4EPSMB1PSMB5
SCHEMBL16346770 0.86 ALDH1A1 (0.52) LTA4HALDH1A1HPGDKDM4ERAB9A
SCHEMBL27593 0.86 PSMB1 (0.69) LTA4HHPGDKDM4EPSMB1PSMB5
SCHEMBL225017 0.86 PSMB1 (0.69) LTA4HHPGDKDM4EPSMB1PSMB5
SCHEMBL30619835 0.85 HRH3 (0.50) LTA4HALDH1A1HPGDPSMB1PSMB5
SCHEMBL1299859 0.85 HPGD (0.64) LTA4HALDH1A1HPGDPSMB1PSMB5
Hydrochloric Acid SCHEMBL5685583 0.84 PSMB1 (0.67) LTA4HHPGDKDM4EPSMB1PSMB5
SCHEMBL9935827 0.84 SIGMAR1 (0.66) KDM4EKMT2ASIGMAR1
SCHEMBL13460612 0.83 LTA4H (0.58) LTA4HALDH1A1HPGDUSP2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9238656-B2 Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders CEPHALON, INC. (US) 2016-01-19 — — US disclosed
US-9238656-B2 Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders CEPHALON, INC. (US) 2016-01-19 — — US disclosed
US-9238656-B2 Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders CEPHALON, INC. (US) 2016-01-19 — — US disclosed
EP-2809671-B1 IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CEPHALON INC (US) 2016-01-13 — — EP disclosed
EP-2809671-B1 IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CEPHALON INC (US) 2016-01-13 — — EP disclosed
EP-2809671-A1 IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Cephalon, Inc. (US) 2014-12-10 — — EP disclosed
US-20140350011-A1 Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders CEPHALON, INC. 2014-11-27 — — US disclosed
US-20140350011-A1 Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders CEPHALON, INC. 2014-11-27 — — US disclosed
US-20140350011-A1 Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders CEPHALON, INC. 2014-11-27 — — US disclosed
WO-2013116291-A1 IMIDAZO [4, 5 - B] PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS CEPHALON, INC. (US) 2013-08-08 — — WO disclosed
EP-0767170-B1 NOVEL 4,6-DIARYLPYRIMIDINE DERIVATIVES AND SALTS THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2002-10-23 — — EP disclosed
US-20020111374-A1 Estrogen receptor modulators CHIRON CORPORATION 2002-08-15 — — US disclosed
US-6387920-B2 ISOXAZOLE COMPOUNDS; FOR TREATING ESTROGEN RECEPTOR-MEDIATED DISORDERS SUCH AS OSTEOPOROSIS, BREAST AND ENDOMETRIAL CANCERS, ATHEROSCLEROSIS, ALZHEIMER'S DISEASE CHIRON CORPORATION 2002-05-14 — — US disclosed
US-20010036956-A1 Estrogen receptor modulators HUEBNER VERENA D (US) 2001-11-01 — — US disclosed
US-6291505-B1 PYRAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST CHIRON CORPORATION 2001-09-18 — — US disclosed
US-6262098-B1 ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST CHIRON CORPORATION 2001-07-17 — — US disclosed
EP-1102755-A1 SUBSTITUTED ISOXAZOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2001-05-30 — — EP disclosed
WO-2000008001-A1 SUBSTITUTED ISOXAZOLE AS ESTROGEN RECEPTOR MODULATORS CHIRON CORPORATION (US) 2000-02-17 — — WO disclosed
US-5786355-A COMPOUNDS FOR TREATMENT OF CANCER, RHEUMATISM, DIABETIC RETINOPATHY OR PSORIASIS TAIHO PHARMACEUTICAL CO., LTD. (JP) 1998-07-28 — — US disclosed
EP-0767170-A1 NOVEL 4,6-DIARYLPYRIMIDINE DERIVATIVES AND SALTS THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 1997-04-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010036956-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 LTA4H 886/4885ALDH1A1 3101/4885HPGD 752/4885
US-20140350011-A1 Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders JAK1, ALK, JAK2 LTA4H 2080/4885ALDH1A1 653/4885HPGD 1770/4885
US-20020111374-A1 Estrogen receptor modulators ESR1, ESR2, GPER1 LTA4H 1438/4885ALDH1A1 3118/4885HPGD 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.